key: cord-0707802-nionn0ns
authors: Estakhr, Mehrdad; Tabrizi, Reza; Ghotbi, Zahra; Shahabi, Saied; Habibzadeh, Adrina; Bashi, Ali; Borhani-Haghighi, Afshin
title: Is facial nerve palsy an early manifestation of COVID-19? A literature review: COVID-19 and Facial Nerve Palsy
date: 2022-04-14
journal: Am J Med Sci
DOI: 10.1016/j.amjms.2022.04.010
sha: d84767f5fa8ed058e404c51ce959249ffce82ab8
doc_id: 707802
cord_uid: nionn0ns

The primary target of SARS-CoV-2 is the respiratory tract; nevertheless, the virus can invade extrapulmonary organs, such as the nervous system. Peripheral facial nerve palsy has been reported in COVID-19 cases as isolated, unilateral, or bilateral in the context of Guillain-Barré syndrome (GBS). In the present study, online databases, including PubMed and Google Scholar, were searched. Studies without focusing on isolated peripheral facial nerve palsy and SARS-CoV-2 were excluded. Finally, 36 patients with facial nerve palsy were included in our study using reverse transcriptase–polymerase chain reaction (RT-PCR) or antibody SARS-CoV-2 positive test. Interestingly, 23 (63.8%) of these patients had no typical history of COVID-19, and facial nerve palsy was their first clinical manifestation. The present study concludes that there is enough evidence to suggest that SARS-CoV-2 infection may present with facial nerve palsy as the initial clinical manifestation.

The COVID-19 epidemic emerged in December 2019 in Wuhan, China, which has rapidly spread worldwide. 1 Besides respiratory symptoms, COVID-19 can cause a variety of symptoms.

Although lung inflammation and respiratory failure are of vital importance, various manifestations have been increasingly described in the last few months, including asymptomatic renal and cardiac abnormalities or nervous system involvement. 2 Neurological symptoms can be the first manifestation of COVID-19 or concomitant of respiratory symptoms, including headaches, hyposmia, hypogeusia, dizziness, confusion, cerebrovascular diseases, Guillain-Barré syndrome (GBS), and encephalopathies. Neurological manifestations were seen in up to 36% of COVID-19 patients, especially in those who suffer from severe respiratory tract infections. 3 Based on previous studies, COVID-19 could lead to peripheral facial nerve palsy via angiotensin-converting enzyme 2 (ACE2) receptors, blood circulation, or invading the olfactory nerves; however, the mechanism is unknown. 4 , 5 Combined facial and trigeminal nerve palsy can potentially occur after SARS-CoV-2 infection. 6 Numerous cases of facial nerve palsies associated with SARS-CoV-2 infection were reported as the first presentation. 7 The COVID-19 pandemic has attracted the attention of physicians as facial nerve palsy cases were increased after the COVID-19 pandemic compared to previous years. 8 Therefore, the present literature review aimed to summarize current studies and case series to suggest facial nerve palsy as the initial clinical presentation of COVID-19.

Online databases, including PubMed and Google Scholar, were searched from January 2020 to July 2020. The following keywords were used: "SARS-CoV-2," "COVID-19," "facial nerve palsy," and "facial paralysis." Cohort studies, case series, and case reports of facial nerve palsy with COVID-19 infection were included. Restrictions were imposed to exclude studies without focusing on isolated peripheral facial nerve palsy and SARS-CoV-2. Nineteen studies are listed in Table 1 .

SARS-CoV-2 infection is typically marked by fever and respiratory symptoms, although neurologic manifestations were described. Among large-scale observational studies in the setting of COVID-19 patients, 36.4% had neurologic findings, including cerebrovascular events, cranial nerve abnormalities, and muscle injuries. 9 Recent studies have reported that SARS-CoV-2-related infection may present with cranial neuropathies, including oculomotor, abducens, and peripheral facial nerve palsies.

Moreover, peripheral facial nerve palsy was described in SARS-CoV-2-positive patients as isolated and unilateral 10 or bilateral in the context of GBS. 11 Wei et al. reported acute unilateral isolated oculomotor nerve palsy in an adult patient with COVID-19 pneumonia. 12 There was no identifying data of the structural cause of oculomotor nerve injury, suggesting that COVID-19 infection might cause acute oculomotor nerve palsy in this case. 12 Oliveira et al.

presented an asymptomatic positive SARS-CoV-2 in a 2-year-old child with acute-onset oculomotor nerve palsy. 13 Studies have shown that young patients with COVID-19 present isolated abducens nerve palsy despite having normal brain imaging, and no clear etiology has been determined to explain those abducens nerve palsies, which may suggest or emphasize the role of SARS-CoV-2. 14,15 Thus, ophthalmologists need to be aware that abducens or oculomotor nerve palsies may represent part of the neurologic spectrum of COVID-19. During the pandemic, global independent centers have observed an increased load of facial peripheral nerve palsy. 16 According to Table 1, 36 patients with facial nerve palsy were included using reverse transcriptase-polymerase chain reaction (RT-PCR) or antibody SARS-CoV-2 positive test. The patients' average age was 32.5 years, except for 10 patients who were excluded due to lack of information. As younger patients might have more potent immune systems, facial palsy might be more common in the younger population of COVID-19 patients. 17 Interestingly, 23 (63.8%) patients had no history of fever, malaise, cough, or any shortness of breath sign, and facial nerve palsy was their first clinical manifestation.

Zammit et al. reported that the facial nerve palsy rate was 2.7% higher than last year.

They conducted a retrospective review of facial nerve palsies from January to June 2020; they compared their findings to the previous year's Liverpool population. 16 During the first phase of the COVID-19 pandemic in Italy (27 February to 3 May 2020(, the incidence of individuals presenting with facial palsy was compared in 6 emergency rooms to the same period in 2019; it was found that cases were younger than those of the previous year and showed a prolonged delay between the onset of facial palsy and seeking medical treatment. 8 This could be attributed to a systemic inflammatory response that predisposes COVID-19 patients to neurological abnormalities.

Neurologic manifestations without typical COVID-19 symptoms became a challenge amid the pandemic. Not only do patients not follow isolation and social distancing in the absence of common symptoms, but medical staff may also underestimate the risk of those patients. Finsterer et al. also reported that facial nerve palsy could be a manifestation of GBS. 18 Regarding the potential risk of transmission in missed diagnosed cases during the pandemic, differential diagnosis of facial nerve palsies should include COVID-19. As initial neurologic manifestations of COVID-19, cranial neuropathies have hitherto been unclear. The number of patients in the literature is limited; thus, the RT-PCR test on the first admission and larger patient groups may help clarify the etiology.

The SARS-CoV-2 genome sequence has 89.1% similarity combined to SARS-like coronaviruses. 19 SARS-CoV-1 has been detected in the CSF and brain tissue of patients, which is the most closely similar to human coronavirus, and also SARS-CoV-2 detection in CSF has been reported. 20 Up to now, shreds of evidence of the neurotropism effect of SARS-CoV-2 have been provided, for instance, involving the cranial nerves (hypogeusia, Bell's palsy, hyposmia, and abducens nerve palsy) or neurological manifestations (headache, dizziness, and impaired consciousness). Many viruses, including influenza, herpes, or human immunodeficiency virus (HIV), can cause neurological diseases by invading the nervous system. Since the neurotropic mechanisms of SARS-CoV- 2 have not yet been established, SARS-CoV-1 and other viruses could play a reference role for SARS-CoV-2.

It has been unclear whether cranial neuropathies, as early neurologic manifestations of COVID-19 infection, arise from the direct viral infiltration of the nervous system or an autoimmune response. Several hypotheses were documented for nervous system involvement in the setting of COVID-19 patients, which can be divided into 2 tenable underlying mechanisms. The first mechanism includes synaptic propagation and the ACE2 receptor virus entranceway. Based on previous studies, coronaviruses can invade CNS by the cribriform plate of the ethmoid, and subsequent invasion of the olfactory neuroepithelium could cause neural death in mice. 21 Coronavirus can permeate via synapses from olfactory nerve neurons to the cardiorespiratory center, named the "theory of synaptic propagation." SARS-CoV-2 may implicate respiratory failures based on this theory. 22 SARS-CoV-2 could directly penetrate sensory nerve endings as other coronaviruses. 23 The trigeminal nerve is thought to serve as an entry point for viruses in several reported cases of conjunctivitis. 24 However, the ACE2 primary entrance receptor view has been accepted in direct neuroinvasion contrasts. ACE2 is widely expressed in the human body, specifically in neurons and some non-neuron cells, mainly astrocytes, oligodendrocytes, and endothelial cells. 5, 25, 26 SARS-CoV-2 enters host cells via binding to the ACE2 receptor with viral surface spike (S) proteins, similar to the SARS-CoV-1 entrance. [27] [28] [29] Furthermore, it can infect macrophages to migrate via the blood-brain barrier (BBB). 30 SARS-CoV-2 affinity to the receptor is almost 20-fold more than SARS-CoV-1, 31 which would explain many neurological manifestations such as headache, nausea, and vomiting in COVID-19 patients. 32 "Cytokine storm" may be the second mechanism regarding endothelial cell involvement. 33, 34, 35 Intracranial cytokine storms could lead to the BBB breakdown, which could be the leading cause of encephalopathy or GBS. 36, 37 An ample body of evidence on patients with COVID-19 has documented severe systemic manifestations, including cytokine storm and coagulopathy. 38 This systemic inflammatory response could be attributed to various factors, particularly infections. 39 It is unassailable that our learnings about SARS-CoV-2 are limited, especially about neurological manifestations. In this regard, neuronal tissue exploration and detailed neurological examination may facilitate our understanding. 5

It is challenging to manage facial nerve palsy during the COVID-19 pandemic due to the potential exposure, probability requirement of isolation, and limited healthcare resources.

Since the absence of common symptoms of COVID-19 has been reported in patients with facial nerve palsy, it is recommended that all protective measures should be taken until the status of COVID-19 is clarified in these patients. Taking a detailed patient's medical history and performing a neurological examination may ultimately lead to a Bell's palsy diagnosis following the elimination of other differential diagnoses and conditions that require immediate treatment. 40 COVID-19 patients with facial nerve palsy should undergo a complete diagnostic workup. In all patients who suddenly manifest peripheral facial paralysis, lumbar puncture is considered a diagnostic procedure. The inflammatory responses of infectious pathogens can be rapidly detected in CSF. The CSF detection of oligoclonal bands, CSF anti-myelin oligodendrocyte glycoprotein (MOG) antibody, CSF anti-neuromyelitis optica (NMO), or ACE level should be considered. Plasma and CSF antibody levels could be measured due to viral (varicella-zoster, herpes simplex, cytomegalovirus, adenovirus, and Epstein-Barr) or Borrelia burgdorferi infections. 41 In some specific cases, human immunodeficiency virus serologic tests may be considerably raised. Magnetic resonance imaging (MRI) of the brain may particularly delineate the brainstem, posterior fossa, or petrous bone. 42, 43 Suggested therapeutic regimes are corticosteroids and antiviral agents and symptom therapy. Steroid edema and swelling reduction may lead to facial nerve decompression, therefore attracting more attention among other regimes. 44 Early treatment immediately after the onset of symptoms (<72 hours) could improve patients' outcomes and reduce auricular pain and nerve damage. 45 The authors recommend a 1-mg/kg/day course of prednisolone and then tapered for 5-10 days. 43, 46 Pain with vesicles in the ear canal could be manifested by zoster infection; in this setting, the combination of antivirals and steroids might be beneficial. 43 Clinical trials that have been performed to date to answer this question are relatively heterogeneous. 47 

Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction

Management of acute ischemic stroke in patients with COVID-19 infection: Report of an international panel

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Rapid Nipah virus entry into the central nervous system of hamsters via the olfactory route

Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms

COVID-19 associated cranial nerve neuropathy: A systematic review

Facial paralysis as the only symptom of COVID-19: A prospective study

Facial palsy during the COVID-19 pandemic

Neurological associations of COVID-19

Pearls and Oy-sters: Facial nerve palsy as a neurological manifestation of Covid-19 infection

Guillain-Barré syndrome in a patient with antibodies against SARS-COV-2

The 2019 novel cornoavirus pneumonia with onset of oculomotor nerve palsy: a case study

Oculomotor nerve palsy in an asymptomatic child with COVID-19

Isolated Cranial Nerve 6 Palsy in 6 Patients With COVID-19 Infection

Acute abducens nerve palsy in a patient with the novel coronavirus disease (COVID-19)

A rise in facial nerve palsies during the coronavirus disease 2019 pandemic

Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?

Guillain-Barre syndrome in 220 patients with COVID-19

Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms

First case of 2019 novel coronavirus in the United States

Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2

Mechanisms of microbial traversal of the blood-brain barrier

Macrophage-mediated optic neuritis induced by retrograde axonal transport of spike gene recombinant mouse hepatitis virus

SARS-CoV-2 in the ocular surface of COVID-19 patients

The Spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains

ACE2 in brain physiology and pathophysiology: evidence from transgenic animal models

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Pathogenetic mechanisms of severe acute respiratory syndrome

Multiple organ infection and the pathogenesis of SARS

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (80-)

Coronavirus disease 2019: What we know

Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic? Neurol (English Ed

Nervous system involvement after infection with COVID-19 and other coronaviruses

COVID-19: consider cytokine storm syndromes and immunosuppression

COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features

Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?

Understanding the Immunologic Characteristics of Neurologic Manifestations of SARS-CoV-2 and Potential Immunological Mechanisms

Cytokine release syndrome

Assessment and management of facial nerve palsy

COVID-19 as a Rare Cause of Facial Nerve Neuritis in a Pediatric Patient

What is the role of imaging in the evaluation of the patient presenting with unilateral facial paralysis? Laryngoscope

The diagnosis and treatment of idiopathic facial paresis (bell's palsy(

Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology

Early treatment with prednisolone or acyclovir in Bell's palsy

Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial

Antiviral treatment for Bell's palsy (idiopathic facial paralysis)

Physical therapy for Bell's palsy (idiopathic facial paralysis)

COVID-19 myocarditis and postinfection Bell's palsy

Peripheral facial paralysis as presenting symptom of COVID-19 in a pregnant woman

Facial palsy as a neurological complication of SARS-CoV-2

Lower motor neuron facial palsy in a postnatal mother with COVID-19

A unique association of bifacial weakness, paresthesia and vestibulocochlear neuritis as post-COVID-19 manifestation in pregnant women: a case report

Bilateral facial nerve palsy associated with COVID-19 and Epstein-Barr virus co-infection

Facial nerve palsy: an atypical clinical manifestation of COVID-19 infection in a family cluster

Facial diplegia, a possible atypical variant of Guillain-Barré Syndrome as a rare neurological complication of SARS-CoV-2

Neurological Manifestations of COVID-19 in Children: A Case of Facial Nerve Palsy

Peripheral facial nerve palsy associated with COVID-19

The great pretender-Bell's palsy secondary to SARS-CoV-2?

Coronavirus Disease-19 Pneumonia with Facial Nerve Palsy and Olfactory Disturbance

Severe acute respiratory syndrome coronavirus 2 as an atypical cause of Bell's palsy in a patient experiencing homelessness

Coronavirus disease 2019 complicated with Bell's palsy: a case report

Bell's palsy in a pediatric patient with hyper IgM syndrome and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Bilateral peripheral facial palsy following asymptomatic COVID-19 infection: a case report

All authors contributed to searching, drafting, or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

None.